OncoSil MedicalOSL 
$0.01-3.70%24h
-3.70%24h
Global rank30694
Market cap$17.37M
Change 7d18.18%
YTD Performance44.44%
SP500 benchmarkOutperform
P/E0
P/S69.81
Revenue$248.75K
Earnings-$7.67M
Dividend yield-
Main Sector
Healthcare
OncoSil Medical (OSL) Stock Overview
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OSL Stock Information
Symbol
OSLAddress
7 Eden Park DriveMacquarie Park, NSW 2113Australia
Founded
-Trading hours
10:00 AM - 4:00 PM AESTWebsite
https://www.oncosil.com.auCountry
🇦🇺 AustraliaPhone Number
61 2 8935 9629OncoSil Medical (OSL) Price Chart
-
Value:-
OncoSil Medical Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.008794955754607203 | N/A |
| Market Cap | $17.37M | N/A |
| Shares Outstanding | 1.97B | 97.87% |
| Employees | 0 | N/A |
| Shareholder Equity | 9.88M | -11.49% |
Valuation | 2023 | Change |
|---|---|---|
| P/S Ratio | 69.81 | N/A |
| P/B Ratio | 1.76 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.7767 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $248.75K | N/A |
| Earnings | -$7.67M | N/A |
| Gross Margin | -3.32 | N/A |
| Operating Margin | -34.62 | N/A |
| Net income margin | -30.85 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $7.76M | N/A |
| Total Debt | $115.56K | N/A |
| Cash on Hand | $6.43M | N/A |
| Debt to Equity | 0.1091 | -5.56% |
| Cash to Debt | $55.68 | 48.99% |
| Current Ratio | $7.16 | -0.68% |
